Affimed begins Phase I recruitment for anti-CD30 drug against Hodgkins

Unable to create scaled Thumbnail image.

Germany-based biotech company Affimed Therapeutics has announced that they have begun Phase I enrollment for the company's anti-CD30 treatment for Hodgkins lymphoma (HL).

Read more about this at CancerTreatment.net.

LymphomaInfo Social